Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Accessibility and prescription of EMA-approved OMPs for HMDs in the 18 individual MetabERN participating countries

From: Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network

  1. * All EU patients were registered in the NL in 2018
  2. ** Marketing authorization under discussion